Title
Treatment efficacy of a titratable oral appliance in obstructive sleep apnea patients : a prospective clinical trial Treatment efficacy of a titratable oral appliance in obstructive sleep apnea patients : a prospective clinical trial
Author
Faculty/Department
Faculty of Medicine and Health Sciences
Publication type
article
Publication
Brussel ,
Subject
Human medicine
Source (journal)
Acta oto-rhino-laryngologica Belgica. - Brussel
Volume/pages
12(2016) :1 , p. 1-8
ISSN
0001-6497
ISI
000372860400001
Carrier
E
Target language
English (eng)
Affiliation
University of Antwerp
Abstract
Purpose: This prospective clinical trial assessed the therapeutic outcomes of patients with obstructive sleep apnea (OSA) treated with a novel duobloc custom-made titratable mandibular advancement device (OAm). Material and methods: The modular Somnomed G2 (R) OAm (Somnomed Europe AG, Zurich, Switzerland) with 'click-to-fit' adjustability provides instant feedback on the mandibular advancement. 161 consecutive patients with established diagnoses of OSA. Dental impressions were made and a bite registration in 75% of the maximal protrusion being the starting protrusion. Treatment response was defined as >= 50% decrease in apnea-hypopnea index (AHI). Treatment success was defined as la) AHI with OAm < 5 events/h sleep or lb) AHI with OAm < 10 events/h. Treatment success and response were combined to define additional criteria: 2a) reduction in AHI >= 50% and AHI < 5 events/h; and 2b) reduction in AHI >= 50% and AHI <10 events/h. Results: In 112 patients AHI decreased significantly from 25 +/- 18/h sleep at baseline to 12 +/- 13/h with the OAm (p <0.001). The visual analogue scoring for snoring (VAS) decreased significantly from 7 3 to 2 2 (p <0.001). Treatment response was achieved in 65 of 112 patients (58%); 31% and 57% of patients were treated successfully according to criteria la and lb, respectively. Furthermore, 31% and 50% of patients were treated successfully according to criteria 2a and 2b, respectively. Conclusions: This clinical trial indicates that treatment with a novel custom-made OAm can reduce the severity of sleep disordered breathing by significantly decreasing the AHI and VAS scores.
E-info
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000372860400001&DestLinkType=RelatedRecords&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000372860400001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848
Full text (open access)
https://repository.uantwerpen.be/docman/irua/2ca262/133248.pdf
Handle